Molecure SA
1.38
EUR
-0.04
(-2.54%)
ISIN
PLONCTH00011
Return %
Stock
S&P 500
1Y
-21.18
14.20
3Y
-66.49
81.12
5Y
-82.96
68.34
Capital Structure
PLN
•
in mil. unless spec.Working Capital
PLN
•
in mil. unless spec.Growth Rates
PLN
•
in mil. unless spec.Quarterly Revenue
PLN
•
in mil. unless spec.Quarterly Earnings Per Share
PLN
•
in mil. unless spec.Quarterly Dividends Per Share
PLN
•
in mil. unless spec.Company Description
- CEO
- Marcin Jan Szumowski
- Full Time Employees
- 53
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Zwirki i Wigury 101 Warsaw MZ Poland 02-089
- IPO Date
- Apr 19, 2018
- Website
- molecure.com
- Similar Companies
- Business
- Molecure S.A. (WSE: MOC) is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapeutics targeting undruggable targets in oncology and other serious diseases. The company develops novel drug candidates through its proprietary platforms, including KL1NGE for KLICK chemistry-based degraders and Transcend for computational design of protein-protein interaction inhibitors; its pipeline features candidates such as OATD-02, a first-in-class oral E3 ligase-based degrader for cancer treatment advancing to Phase I clinical trials, and MCN-101, a p53-MDM2 protein-protein interaction inhibitor for solid tumors. Molecure operates primarily in the biopharmaceutical industry, targeting pharmaceutical companies and clinical research organizations as partners for licensing and co-development, with geographic focus on Europe and global clinical operations. Founded in 2012 and headquartered in Warsaw, Poland, the company leverages expertise in medicinal chemistry, structural biology, and AI-driven drug design to advance its portfolio. Molecure maintains subsidiaries and collaborations across Europe, with no parent company. In the past 1-2 years, Molecure has achieved key milestones including positive preclinical data for OATD-02 leading to IND-enabling studies initiation in 2024 and planned Phase I entry in 2025; a strategic research collaboration and licensing agreement with a major global pharmaceutical partner for its KL1NGE platform in late 2024; and expansion of its Transcend program with new hit series nominations for additional oncology targets. These developments follow successful completion of Phase Ib dose escalation for its earlier candidate MCB-613, which supported strategic pipeline prioritization.